Chinese Japanese Germany Korea
ChemicalBook >> CAS DataBase List >>Entrectinib

Entrectinib

Entrectinib Structure
Entrectinib structure
CAS No.
1108743-60-7
Chemical Name:
Entrectinib
Synonyms
N-[5-[(3,5-Difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]benzamide;RXDX-101;N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide;CS-1589;NMS-E628;ROZLYTREK);Entrectinib;entrecitinib;NMS-01191372);13C,2H3]-Entrectinib
CBNumber:
CB93040787
Molecular Formula:
C31H34F2N6O2
Molecular Weight:
560.64
MDL Number:
MFCD28129099
MOL File:
1108743-60-7.mol
MSDS File:
SDS
TDS File:
TDS
Last updated:2026-09-10 08:17:50
Request For Quotation

Entrectinib Properties

Boiling point 717.5±60.0 °C(Predicted)
Density 1.340±0.06 g/cm3(Predicted)
storage temp. Store at -20°C
solubility ≥28.05 mg/mL in DMSO; insoluble in H2O; ≥9.82 mg/mL in EtOH with ultrasonic
form solid
pka 12.01±0.43(Predicted)
color Off-white to light yellow
InChIKey HAYYBYPASCDWEQ-UHFFFAOYSA-N
SMILES C(NC1C2=C(NN=1)C=CC(CC1=CC(F)=CC(F)=C1)=C2)(=O)C1=CC=C(N2CCN(C)CC2)C=C1NC1CCOCC1
NCI Dictionary of Cancer Terms entrectinib
FDA UNII L5ORF0AN1I
NCI Drug Dictionary entrectinib
ATC code L01EX14

SAFETY

Risk and Safety Statements

Symbol(GHS)  Exclamation Mark (GHS07)
GHS07
Signal word  Warning
Hazard statements  H315-H319-H335
Precautionary statements  P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P321-P362+P364-P332+P313-P337+P313-P403+P233-P405-P501
NFPA 704
0
2 0

Entrectinib price More Price(50)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 19476 Entrectinib ≥98% 1108743-60-7 1mg $40 2026-04-30 Buy
Cayman Chemical 19476 Entrectinib ≥98% 1108743-60-7 5mg $132 2026-04-30 Buy
Cayman Chemical 19476 Entrectinib ≥98% 1108743-60-7 10mg $246 2026-04-30 Buy
ChemScene CS-4343 Entrectinib 99.79% 1108743-60-7 5mg $71 2026-06-04 Buy
ChemScene CS-4343 Entrectinib 99.79% 1108743-60-7 10mg $107 2026-06-04 Buy
Product number Packaging Price Buy
19476 1mg $40 Buy
19476 5mg $132 Buy
19476 10mg $246 Buy
CS-4343 5mg $71 Buy
CS-4343 10mg $107 Buy

Entrectinib Chemical Properties, Uses, Production

Description

Entrectinib is used to treat metastatic (lung cancer that has already spread) non-small cell lung cancer (NSCLC) that is caused by a gene called ROS1. This medicine is also used to treat solid tumors (cancer) that are caused by certain abnormal NTRK genes and have spread or if surgery to remove the cancer is likely to cause severe complications, and there is no acceptable treatment option or the cancer grew or spread on other treatments.

Effect and benefit

Entrectinib belongs to the group of medicines called antineoplastics (cancer medicines). It works by interfering with the growth of cancer cells, which are eventually destroyed.

Mechanism of action

An inhibitor of tropomyosin receptor tyrosine kinases (TRKs) TRKA, TRKB, and TRKC (encoded by the neurotrophic tyrosine receptor kinase [NTRK] genes NTRK1, NTRK2, and NTRK3, respectively), proto-oncogene tyrosine-protein kinase ROS1 (ROS1), and anaplastic lymphoma kinase (ALK); also, inhibits JAK2 and TNK2. Major active metabolite of entrectinib, M5, showed similar in vitro activity against TRK, ROS1, and ALK. Fusion proteins that include TRK, ROS1, or ALK kinase domains can drive tumorigenic potential through hyperactivation of downstream signaling pathways, leading to unconstrained cell proliferation.

Safety

Entrectinib exhibits hepatic metabolism through cytochrome P450 (CYP) 3A and therefore interacts with moderate-strong CYP3A inhibitors and inducers. In addition, due to its effects on the QTcF interval, use of entrectinib should be avoided with other drugs known to prolong the QT/QTc interval.

Pharmacology

Entrectinib, is a weak P-gp substrate that can sustain CNS exposure based on our novel in vitro and in vivo experiments. This is consistent with the observed preclinical and clinical efficacy of entrectinib in neurotrophic tropomyosin receptor kinase (NTRK) and ROS1 fusion-positive CNS tumors and secondary CNS metastases.

Description

Entrectinib (RXDX-101, Ignyta Pharmaceuticals, San Diego, CA, USA) is a small molecule that inhibits the tyrosine kinases TRKA/B/C, ROS1, and ALK (Table1). It has a preclinical median inhibitory concentration (IC50) of 7nm against ROS1, higher than crizotinib [95, 96]. Entrectinib was specifically designed to cross the blood-brain barrier [95].

Description

Entrectinib is an inhibitor of TrkA (IC50 = 1.7 nM), TrkB (IC50 = 0.1 nM), and TrkC (IC50 = 0.1 nM), as well as C-ros oncogene 1 (ROS1; IC50 = 0.2 nM) and anaplastic lymphoma kinase (ALK; IC50 = 1.6 nM). Entrectinib blocks proliferation of ALK-dependent cell lines, including those with L1196M or C1156Y resistance mutations, and inhibits ALK‐dependent signaling. It has been shown to inhibit the growth of a non-small cell lung cancer cell line bearing an EML4-ALK rearrangement. In mice bearing various Trk, ROS1, or ALK-driven xenografts, entrectinib has been shown to induce tumor regression.

Uses

Entrectinib, also known as RXDX-101 and NMS-E628, is an oral small molecule inhibitor of TrkA, TrkB and TrkC, as well as ROS1 and ALK, with high potency and selectivity. RXDX-101 has demonstrated potent pharmacological activity in preclinical studies and has the potential to be first-in-class against the Trk family of kinases. PXDX-101 has been well tolerated in patients with advanced solid tumors. PXDX-101 is currently in clinical trials, and is being developed by Ignyta.

brand name

Rozlytrek

General Description

Class: receptor tyrosine kinase; Treatment: NTRK tumors, ROS-1 NSCLC; Other name: RXDX-101; Elimination half-life = 20 h; Protein binding >99%

Clinical Use

Entrectinib demonstrated potent antitumor effects in tumor cell lines and patient-derived xenograft (PDX) tumor models in preclinical studies. Furthermore, entrectinib can cross the blood–brain barrier (BBB) to impact primary brain tumors and brain metastases in patients with NTRK1/ NTRK2/NTRK3, ROS1, and ALK fusion-driven cancers.

Synthesis

Synthesis route of Entrectinib
Entrectinib synthesis
Entrectinib

in vitro

entrectinib potently and selectively inhibits the in vitro growth of alk-driven tumors, with confirmed mechanism of action [1].

in vivo

since entrectinib is able to pass the blood-brain barrier, the compound was also tested for efficacy in an xenograft model with alk positive nsclc tumors. mri imaging demonstrated that entrectinib was able to effectively and control the growth of these intracranial tumors dose-dependently, leading to increased survival [1].

target

Primary targets:TRK, ROS1, ALK

References

[1] elena ardini, maria menichincheri, patrizia banfi, daniele casero, m. laura giorgini, m. beatrice saccardo, nadia amboldi, nilla avanzi, paolo orsini, antonella isacchi, enrico pesenti, arturo galvani. the alk inhibitor nms-e628 also potently inhibits ros1 and induces tumor regression in ros-driven models. [abstract]. in: proceedings of the 104th annual meeting of the american association for cancer research; 2013 apr 6-10; washington, dc. philadelphia (pa): aacr; cancer res 2013;73(8 suppl):abstract nr 2092. doi:10.1158/1538-7445.am2013-2092

Entrectinib synthesis

1108745-38-5
1108743-60-7
Synthesis of Entrectinib from Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)(2,2,2-trifluoroacetyl)amino]-

Entrectinib Preparation Products And Raw materials

Raw materials

Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)(2,2,2-trifluoroacetyl)amino]- Benzamide, 2-?amino-?N-?[5-?[(3,?5-?difluorophenyl)?methyl]?-?1H-?indazol-?3-?yl]?-?4-?(4-?methyl-?1-?piperazinyl)?- 3,5-Difluorobenzyl bromide 5-(3,5-difluorobenzyl)-2-fluorobenzonitrile 4-Fluoro-2-nitrobenzoic acid
tert-butyl 4-(4-methylpiperazin-1-yl)-2-nitrobenzoate 4-Fluoro-2-Nitro-Benzoic Acid Tert-Butyl Ester tert-butyl 2-amino-4-(4-methylpiperazin-1-yl)benzoate 5-(3,5-difluorobenzyl)-1H-indazol-3-amine 4-(4-methylpiperazin-1-yl)-2-[(tetrahydropyran-4-yl)(2,2,2-trifluoroacetyl)amino]benzoic acid tert-butyl ester
4-(4-methylpiperazin-1-yl)-2-[(tetrahydropyran-4-yl)amino]benzoic acid tert-butyl ester 4-(4-methylpiperazin-1-yl)-2-[(tetrahydropyran-4-yl)(2,2,2-trifluoroacetyl)amino]benzoic acid trifluoroacetate 3-Cyano-4-fluorobenzeneboronic acid Tetrahydro-4H-pyran-4-one

1of3

Preparation Products

Entrectinib Suppliers

Global Suppliers ( 227)
Supplier Tel Email Country ProdList Advantage
Chengdu Celes Technology Co., Ltd 19982073091 2538834896@qq.com China 78 58
Shanghai Biobond Pharmaceutical Co.,Ltd. 21-68719686 18917373795; sales@sh-biobond.cn China 86 58
JINAN RUIFENG PHARMACEUTICAL TECHNOLOGY CO.,LTD 18668921571 liujnlz@126.com China 22 58
Changzhou Borl Biotechnology Co.,LTD 13656121842 luyan0021@163.com China 265 58
Shanghai Boyle Chemical Co., Ltd. sales@boylechem.com China 2915 55
Chembest Research Laboratories Limited 021-20908456 sales@BioChemBest.com China 5996 61
WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd. 17702719238 sales@sun-shinechem.com China 1197 64
Dalian Meilun Biotech Co., Ltd. 0411-62910999 13889544652 sales@meilune.com China 4765 58
Shanghai Hope Chem Co., Ltd.， +21-18501659228 18501659228 info@hope-chem.com China 538 55
Haoyuan Chemexpress Co., Ltd. 021-58950125 info@chemexpress.com China 7545 61
Supplier Advantage
Chengdu Celes Technology Co., Ltd 58
Shanghai Biobond Pharmaceutical Co.,Ltd. 58
JINAN RUIFENG PHARMACEUTICAL TECHNOLOGY CO.,LTD 58
Changzhou Borl Biotechnology Co.,LTD 58
Shanghai Boyle Chemical Co., Ltd. 55
Chembest Research Laboratories Limited 61
WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd. 64
Dalian Meilun Biotech Co., Ltd. 58
Shanghai Hope Chem Co., Ltd.， 55
Haoyuan Chemexpress Co., Ltd. 61

Related articles

  • How to synthesize Entrectinib
  • Entrectinib is an orally available, CNS-active, selective inhibitor of the tyrosine kinases tropomyosin receptor kinase (Trk) ....
  • Jan 18,2024
  • Entratinib's mechanism of action
  • Entritinib was approved for marketing in Japan on June 19, 2019, and was approved by the FDA on August 15, 2019 for the treatm....
  • Oct 26,2020

View Latest Price from Entrectinib manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
Entrectinib pictures 2026-09-10 Entrectinib
1108743-60-7
 $35.00-81.00 99.67% 10g TargetMol Chemicals Inc.
Entrectinib pictures 2026-09-03 Entrectinib
1108743-60-7
 1kg ＞99.5% by HPLC 100kg/month Zison Pharmaceutical (Shandong) Co., Ltd.
Entrectinib pictures 2026-08-25 Entrectinib
1108743-60-7
 $55.00-550.00 10kg 0.99 20tons Zibo Hangyu Biotechnology Development Co., Ltd
  • Entrectinib pictures
  • Entrectinib
    1108743-60-7
  • $35.00-81.00
  • 99.67%
  • TargetMol Chemicals Inc.
  • Entrectinib pictures
  • Entrectinib
    1108743-60-7
  • ＞99.5% by HPLC
  • Zison Pharmaceutical (Shandong) Co., Ltd.
  • Entrectinib pictures
  • Entrectinib
    1108743-60-7
  • $55.00-550.00
  • 0.99
  • Zibo Hangyu Biotechnology Development Co., Ltd

Entrectinib Spectrum

Entrectinib(1108743-60-7)MSEntrectinib(1108743-60-7)1HNMR

1108743-60-7 (Entrectinib) Related Search:

Entospletinib (GS-9973) Regorafenib monohydrate Brigatinib lenvatinib Mesylate Dabrafenib
Trametinib Regorafenib Neratinib Poziotinib (HM781-36B) Dacomitinib (PF299804)
Cabozantinib Malate Cediranib Maleate Crizotinib Afatinib (BIBW 2992) Lorlatinib
AZD-9291 Nintedanib esylate Olaparib

1of4

Entrectinib Entrectinib(NMS-E628) Entrectinib,NMS-E628,RXDX-101 entrecitinib Entrectinib(RXDX-101) NMS-E628 CS-1589 NMS E628; RXDX-101;NMSE628; RXDX 101;NMS-E628; RXDX101 RXDX101; RXDX 101; RXDX-101; NMS E628; NMSE628; NMS-E628; ENTRECTINIB Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]- ROZLYTREK) 13C,2H3]-Entrectinib Biopterin Impurity 4 Entrectinib, 10 mM in DMSO NMS-01191372) N-[5-[(3,5-Difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]benzamide N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide RXDX-101 1108743-60-7 C31H34F2N6O2 API API